IPO Relay Therapeutics
Funds raised in 2016-2018
Invest in IPO Relay Therapeutics
Relay Therapeutics (RLAY) has built its own Dynamo platform to integrate an array of leading edge experimental and computational approaches, which allows them to apply understanding of protein structure and motion to drug discovery. The company was founded in 2016 in Boston, US.
In aggregate, RLAY team has previously submitted over 70 INDs and 20 NDAs and contributed to the development of more than 20 approved products. Members of the management team have held leadership positions at companies that have successfully discovered, developed and commercialized therapies for various cancers and devastating rare diseases. These companies include Allergan, Algeta, Blueprint Medicines, Eli Lilly, Merck, Novartis, Sanofi, and Vertex.
The global solid tumor cancer treatment market was valued at US$ 121B in 2018 and is expected to reach US$ 425B by 2027, expanding at a CAGR of 15.0% from 2019 to 2027.
The company's lead candidate RLY-1971, an inhibitor of Src homology region 2 domain-containing phosphatase-2 (SHP2), began a Phase 1 trial in patients with advanced solid tumors in the 1Q 2020. In the future, if RLY-1971 advances to earlier lines of treatment, Relay believes it could potentially have applicability to approximately 290,000 patients annually in the U.S.
The company has never generated revenue from product sales and may never be profitable. This is a biotech company without an approved product. The overall risk is high.
At the upper end of the price range, the company's IPO capitalization will be $1.5B. This is more than average for a biotechnological company at an early stage of product development ($500-700 million). There is a risk of high IPO valuation, which may lead to a decrease in the value of shares after the IPO.
RLAY intends to raise $250 million from an IPO of its common stock at about $1.5B valuation. Relay Therapeutics has raised a total of $520M in funding over 3 rounds.
Biotech IPOs have demonstrated high returns of about 95% over the past 6 months. The most recent offerings inlcude Forma Therapeutics +118%, ADC Therapeutics +128%, Vaxcyte +80%. The expected return on investment is significant (above 40%).
2-3 weeks before the start of the company publishes information about the opening of trading: financial statements for 3 years, a description of the company's business, plans for the future, as well as the risks that management sees in their own business. We analyze such offers and publish the best ones. Investors apply for deposits. Before the deadline for applications, you can change the request or cancel it.
We submit one large application for the purchase of shares by pre-subscription with reduced price to large investors. The application may be rejected in part or in full. Over the past three years, our applications have been rejected only three times. The next day, or every other day, we'll know at what price and at what percentage the order is executed, and we'll post it on «The my investment page».
The price of shares is rising from the first day due to the demand of investors deprived of the opportunity to buy shares before trading. Most of the stocks we've been recommending buying over the past three years have been starting to trade on the stock exchange at tens of percent higher than the price at which customers bought the shares. There comes a Lock up period when it is forbidden to sell shares purchased by subscription. Typically lasts 3 months.
After the expiration of the Lock Up period, the investment is automatically closed and the investor receives a profit on account of the deduction commissions UT. You can always view the results of your past investments in investment archive.
Although no shares are allowed to be sold during the lock-up period, our traders seek to offer investors fixed profit by way of using various financial instruments, including forwards, options, short positions etc.
From the investor’s point of view this means that he or she may close an investment by paying a certain part of its value (as a rule, approximately 15 percent). This is due to high prices for the instruments which are employed to ensure availability of fixed profit. As such, you shall press any relevant button in the Investor Account as soon as it is active.
The closing procedure is similar to commencement of investment business. You shall file a bid which is executed within a business day by UT. So, your investment is closed at the price currently prevailing on the stock exchange. However, we rarely recommend using this feature, since upon expiry of an applicable lock-up period the average performance is higher.
3 per cent of the share price. This fee is charged as soon as your investment bid is confirmed.
1.75 per cent of the purchase price paid for your shares as soon as trading is closed. This fee is charged upon closure of any relevant investment.
20 per cent of the profit your derive. This fee is charged only if you show positive performance as of the moment any relevant investment is closed.
TO EARLY EXIT
Usually, 15 per cent (depends on the stock exchange environment). It is calculated per each investment individually.
Our risk managers ensure proper support throughout the entire transaction. Moreover, you may call them on +7 495 646-15-57 or 8 800 333-66-81 or visit our office, if a more detailed discussion is needed.
IN THE PROFIT FROM THE FIRST DAY
Such an approach allows it to limit extra risks related to bankruptcy of start-ups and considerably increase profit vs investors purchasing shares on open Market.
LOW ENTRY THRESHOLD
Millions of dollars are required to buy shares on a subscription basis. We have generated a pool of traders and investors which enables any newbie to participate in any transaction as aforesaid by investing just USD50 or more.